Results 81 to 90 of about 737,831 (320)

Goodbye flat lymphoma biology

FEBS Letters, EarlyView.
Three‐dimensional (3D) biological systems have become key tools in lymphoma research, offering reliable in vitro and ex vivo platforms to explore pathogenesis and support precision medicine. This review highlights current 3D non‐Hodgkin lymphoma models, detailing their features, advantages, and limitations, and provides a broad perspective on future ...
Carla Faria, Cèlia Dobaño‐López, Patricia Pérez‐Galán, Christine Bezombes   +3 more
wiley   +1 more source

Availability and affordability of treatment for Human African Trypanosomiasis. [PDF]

, 2001
Human African Trypanosomiasis (HAT) is a re-emerging disease whose usual treatments are becoming less efficient because of the increasing parasite resistance.
Etchegorry, M, Helenport, J, Jannin, J, Legros, D, Pecoul, B   +4 more
core   +3 more sources

From omics to AI—mapping the pathogenic pathways in type 2 diabetes

FEBS Letters, EarlyView.
Integrating multi‐omics data with AI‐based modelling (unsupervised and supervised machine learning) identify optimal patient clusters, informing AI‐driven accurate risk stratification. Digital twins simulate individual trajectories in real time, guiding precision medicine by matching patients to targeted therapies.
Siobhán O'Sullivan, Lu Qi, Pierre Zalloua   +2 more
wiley   +1 more source

The anabolic steroid stanozolol is a potent inhibitor of human MutT homolog 1

FEBS Letters, EarlyView.
MutT homolog 1 (MTH1) is a member of the NUDIX superfamily of enzymes and is an anticancer drug target. We show that stanozolol (Stz), an anabolic steroid, is an unexpected nanomolar inhibitor of MTH1. The X‐ray crystal structure of the human MTH1–Stz complex reveals a unique binding scaffold that could be utilized for future inhibitor development ...
Emma Scaletti Hutchinson, Robert Gustafsson Westergren, Ingrid Almlöf, Ann‐Sofie Jemth, Martin Scobie, Ulrika Warpman Berglund, Thomas Helleday, Pål Stenmark   +7 more
wiley   +1 more source

Leishmania donovani develops resistance to drug combinations.

PLoS Neglected Tropical Diseases, 2012
Drug combinations for the treatment of leishmaniasis represent a promising and challenging chemotherapeutic strategy that has recently been implemented in different endemic areas.
Raquel García-Hernández, José Ignacio Manzano, Santiago Castanys, Francisco Gamarro   +3 more
doaj   +1 more source

Mode of action and choice of antimalarial drugs for intermittent preventive treatment in infants.

, 2009
Intermittent preventive treatment in infants (IPTi) is an effective and safe malaria control strategy. However, it remains unclear what antimalarials should be used to replace sulfadoxine-pyrimethamine (SP) when and where SP is no longer an effective ...
Cairns, Matthew, Gosling, Roly, Gesase, Samwel, Mosha, Jacklin, Greenwood, Brian, Chandramohan, Daniel   +5 more
core   +1 more source

One-Step Generation of a Drug-Releasing Hydrogel Microarray-On-A-Chip for Large-Scale Sequential Drug Combination Screening [PDF]

, 2019
Large-scale screening of sequential drug combinations, wherein the dynamic rewiring of intracellular pathways leads to promising therapeutic effects and improvements in quality of life, is essential for personalized medicine to ensure realistic cost and ...
Bae, Hyung Jong, Jeong, Yunjin, Kim, Jiyun, Kim, Su Deok, Kwon, Sunghoon, Lee, Amos Chungwon, Lee, Daewon, Lee, Sumin, Lee, Yongju, Oh, Dong Yoon, Song, Seo Woo   +10 more
core   +1 more source

Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial–mesenchymal transition and tumor‐infiltrating lymphocytes

Molecular Oncology, EarlyView.
Epithelial–mesenchymal transition (EMT) and tumor‐infiltrating lymphocytes (TILs) are associated with early breast cancer response to neoadjuvant chemotherapy (NAC). This study evaluated EMT and TIL shifts, with immunofluorescence and RNA sequencing, at diagnosis and in residual tumors as potential biomarkers associated with treatment response.
Françoise Derouane, Jérôme Ambroise, Cédric van Marcke, Mieke Van Bockstal, Martine Berlière, Christine Galant, Hélène Dano, Médina Lougué, Elena Benidovskaya, Guy Jerusalem, Vincent Bours, Claire Josse, Jérôme Thiry, Aurélie Daumerie, Caroline Bouzin, Cyril Corbet, François P. Duhoux   +16 more
wiley   +1 more source

Modeling Tumor Clonal Evolution for Drug Combinations Design [PDF]

, 2018
Cancer is a clonal evolutionary process. This presents challenges for effective therapeutic intervention, given the constant selective pressure toward drug resistance. Mathematical modeling from population genetics, evolutionary dynamics, and engineering
Hemann, Michael, Lauffenburger, Douglas A, Zhao, Boyang   +2 more
core   +1 more source

Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression

Molecular Oncology, EarlyView.
Immune status significantly influences cancer progression. This study used plasma proteomics to analyze benign 67NR and malignant 4T1 breast tumor models at early and late tumor stages. Immune‐related proteins–osteopontin (Spp1), lactotransferrin (Ltf), calreticulin (Calr) and peroxiredoxin 2 (Prdx2)–were associated with systemic myeloid‐derived ...
Yeon Ji Park, Jae Won Oh, Hyewon Chung, Jung Won Kwon, Yi Rang Na, Kwang Pyo Kim, Seung Hyeok Seok   +6 more
wiley   +1 more source